- Home
- PKE vs FULC Comparison
PKE vs FULC Comparison
Compare PKE & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PKE
- FULC
- Stock Information
- Founded
- PKE 1954
- FULC 2015
- Country
- PKE United States
- FULC United States
- Employees
- PKE N/A
- FULC N/A
- Industry
- PKE Military/Government/Technical
- FULC Biotechnology: Pharmaceutical Preparations
- Sector
- PKE Industrials
- FULC Health Care
- Exchange
- PKE Nasdaq
- FULC Nasdaq
- Market Cap
- PKE 378.7M
- FULC 372.2M
- IPO Year
- PKE N/A
- FULC 2019
- Fundamental
- Price
- PKE $19.01
- FULC $7.32
- Analyst Decision
- PKE
- FULC Buy
- Analyst Count
- PKE 0
- FULC 8
- Target Price
- PKE N/A
- FULC $7.13
- AVG Volume (30 Days)
- PKE 91.9K
- FULC 398.4K
- Earning Date
- PKE 10-14-2025
- FULC 11-12-2025
- Dividend Yield
- PKE 2.60%
- FULC N/A
- EPS Growth
- PKE 4.18
- FULC N/A
- EPS
- PKE 0.34
- FULC N/A
- Revenue
- PKE $63,456,000.00
- FULC N/A
- Revenue This Year
- PKE N/A
- FULC N/A
- Revenue Next Year
- PKE N/A
- FULC N/A
- P/E Ratio
- PKE $55.95
- FULC N/A
- Revenue Growth
- PKE 16.60
- FULC 2752.05
- 52 Week Low
- PKE $11.97
- FULC $2.32
- 52 Week High
- PKE $20.73
- FULC $8.50
- Technical
- Relative Strength Index (RSI)
- PKE 56.02
- FULC 57.81
- Support Level
- PKE $18.19
- FULC $6.69
- Resistance Level
- PKE $19.31
- FULC $7.50
- Average True Range (ATR)
- PKE 0.67
- FULC 0.41
- MACD
- PKE -0.06
- FULC 0.06
- Stochastic Oscillator
- PKE 57.75
- FULC 63.82
About PKE Park Aerospace Corp.
Park Aerospace Corp designs is an aerospace company which develops and manufactures solution and hot-melt composite materials used to produce composite structures for the aerospace markets. Its composite materials include film adhesives and lightning strike protection materials. Its composite materials are used to produce primary and secondary structures for jet engines, large and regional transport aircraft, military aircraft, Unmanned Aerial Vehicles (UAVs commonly referred to as drones), business jets, general aviation aircraft and rotary wing aircraft. The Company's products are sold to customers in North America, Asia and Europe.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.